Balyasny Asset Management
PCRX icon

Balyasny Asset Management’s Pacira BioSciences PCRX Stock Holding History

Balyasny Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.41M Sell
106,418
-839,561
-89% -$18.7M ﹤0.01% 1703
2025
Q4 		$24.5M Sell
945,979
-939,092
-50% -$22.3M 0.03% 620
2025
Q3 		$48.6M Sell
1,885,071
-245,662
-12% -$6.03M 0.06% 374
2025
Q2 		$50.9M Buy
2,130,733
+565,288
+36% +$14.2M 0.08% 322
2025
Q1 		$38.9M Buy
1,565,445
+1,131,239
+261% +$27.1M 0.06% 373
2024
Q4 		$8.18M Buy
+434,206
New +$7.62M 0.01% 1047
2023
Q3 		– Sell
-644,738
Closed -$25.8M – 2610
2023
Q2 		$25.8M Buy
644,738
+615,047
+2,071% +$25.4M 0.06% 441
2023
Q1 		$1.21M Buy
+29,691
New +$1.18M ﹤0.01% 1672
2019
Q3 		– Sell
-188,752
Closed -$8.21M – 1478
2019
Q2 		$8.21M Buy
+188,752
New +$8.01M 0.05% 460
2019
Q1 		– Sell
-41,978
Closed -$1.81M – 1584
2018
Q4 		$1.81M Buy
41,978
+1,419
+3% +$66.2K 0.01% 744
2018
Q3 		$1.99M Sell
40,559
-14,358
-26% -$621K 0.01% 978
2018
Q2 		$1.76M Sell
54,917
-406,185
-88% -$14M 0.01% 970
2018
Q1 		$14.4M Buy
461,102
+83,389
+22% +$2.97M 0.06% 417
2017
Q4 		$17.2M Buy
377,713
+312,813
+482% +$12.4M 0.05% 455
2017
Q3 		$2.44M Sell
64,900
-137,309
-68% -$5.53M 0.01% 906
2017
Q2 		$9.64M Buy
202,209
+41,231
+26% +$1.91M 0.04% 547
2017
Q1 		$7.34M Sell
160,978
-14,281
-8% -$617K 0.03% 596
2016
Q4 		$5.66M Sell
175,259
-99,603
-36% -$3.32M 0.03% 656
2016
Q3 		$9.41M Buy
274,862
+229,732
+509% +$9M 0.05% 400
2016
Q2 		$1.52M Sell
45,130
-226,037
-83% -$11.1M 0.01% 711
2016
Q1 		$14.4M Buy
+271,167
New +$15.9M 0.09% 311
2015
Q4 		– Sell
-228,997
Closed -$9.41M – 1399
2015
Q3 		$9.41M Buy
+228,997
New +$14M 0.07% 356

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's PCRX Position: Q1 2026 in Review

Balyasny Asset Management reduced its Pacira BioSciences (PCRX) stake by 89% in Q1 2026, selling an estimated $18.7M and leaving 106,418 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

Balyasny Asset Management first reported a position in PCRX in Q3 2015 and has held it in 22 quarters since. The position peaked at $50.9M in Q2 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Balyasny Asset Management held 106,418 shares of Pacira BioSciences worth $2.41M as of Q1 2026.
  • Balyasny Asset Management sold 839,561 Pacira BioSciences shares in Q1 2026, an estimated $18.7M.
  • Pacira BioSciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1703 holding.
  • Balyasny Asset Management first reported a position in Pacira BioSciences in Q3 2015 and has held it in 22 quarters since.
  • Balyasny Asset Management's Pacira BioSciences position peaked at $50.9M in Q2 2025.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.